Using advanced MRI to predict how pancreatic cancer patients respond to treatment
Official title: Translating Hyperpolarized 13C MRI as a Novel Tool to Predict Treatment Response in Pancreatic Cancer
Funded at University of California, San Francisco · NIH-11002701 · Data updated 2026-11-12
This study is testing a new imaging technique to help doctors see how well treatments are working for patients with pancreatic cancer, so they can make better decisions about care and potentially improve outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $670,223 |
| NIH project number | 5R01CA280071-02 |
| Project ID | NIH-11002701 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with localized disease who may be eligible for neoadjuvant therapy.
✕Less likely to help
Patients with advanced, non-resectable pancreatic cancer who are not candidates for surgery may not benefit from this research.
What this research studies
This research aims to develop a novel imaging technique using hyperpolarized 13C MRI to monitor and predict treatment responses in patients with pancreatic ductal adenocarcinoma (PDA). By utilizing this advanced imaging method, the study seeks to provide more accurate and timely assessments of how well patients are responding to therapies, particularly in cases where surgery may be an option. The goal is to improve clinical decision-making by identifying effective treatments sooner and potentially guiding patients towards better outcomes. This approach addresses the limitations of current assessment tools that often fail to provide early indicators of treatment efficacy.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for patients with pancreatic cancer, ultimately improving survival rates.
How similar studies have gone: Similar research using advanced imaging techniques has shown promise in other cancer types, suggesting that this approach could be beneficial for pancreatic cancer as well.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Gordon, Jeremy William — University of California, San Francisco
- Study coordinator: Gordon, Jeremy William
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.